Acute coronary syndrome in the oncology patient: An avoidable event?

Rev Port Cardiol (Engl Ed). 2018 Sep;37(9):791.e1-791.e4. doi: 10.1016/j.repc.2017.04.010. Epub 2018 May 24.
[Article in English, Portuguese]

Abstract

5-Fluorouracil is a first-line agent in several cancer-therapy regimens. Cardiotoxicity is common, with coronary artery disease being an important risk factor. We report the case of an acute coronary syndrome presumably induced by 5-FU, in a patient with previously unknown and asymptomatic coronary artery disease, with an estimated intermediate risk for cardiovascular events. Pre-chemotherapy risk evaluation and optimal patient care are still not standardized in this clinical scenario.

Keywords: 5‐FU; Angina Pectoris; Angina pectoris; Cardiotoxicidade; Cardiotoxicity.

Publication types

  • Case Reports

MeSH terms

  • Acute Coronary Syndrome / chemically induced*
  • Acute Coronary Syndrome / complications*
  • Acute Coronary Syndrome / diagnostic imaging
  • Acute Coronary Syndrome / surgery
  • Angioplasty
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Colonic Neoplasms / complications*
  • Colonic Neoplasms / drug therapy
  • Duodenal Neoplasms / complications
  • Duodenal Neoplasms / drug therapy
  • Electrocardiography
  • Fluorouracil / adverse effects*
  • Fluorouracil / therapeutic use
  • Humans
  • Male
  • Middle Aged

Substances

  • Antineoplastic Agents
  • Fluorouracil